The coronavirus pandemic has thrown a wrench into plans for hundreds of clinical trials seeking therapies for diseases beyond Covid-19. But some investigators and sponsors are trying to push ahead, tailoring ways to keep patients enrolled while keeping them safe and to ensure the trial can still produce rigorous evidence of whether or not a drug works.
“The problem that we all want to avoid is that despite our best efforts, the results from a given clinical trial will turn out to be so incomplete or unreliable as to make them uninterpretable,” Pfizer chief medical officer Mace Rothenberg said during a webinar last week.
About the Author Reprints
